Framing
- Systemic cancer therapy toxicity spans haematological (bone marrow suppression), gastrointestinal (nausea, vomiting, diarrhoea, mucositis), and organ-specific (cardiomyopathy, interstitial lung disease, peripheral neuropathy, alopecia) effects - each with a distinct causative drug class, time course, and monitoring strategy
- Anticipatory management (prophylactic antiemetics, growth factor support, baseline cardiac/pulmonary function assessment before cardiotoxic/pneumotoxic agents) is often more effective than reactive treatment once toxicity has developed, making pre-treatment risk assessment a core part of safe prescribing
What sits under this topic
- See for treatment-related cytopenias and infection risk
- See , , , and for gastrointestinal toxicity
- See and for organ-specific cardiac/pulmonary toxicity
- See and for neurological and dermatological toxicity
2 of 2 sections written · drafted 2026-09-14